Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

CONNEXIN 43 FOR USE IN THE TREATMENT OF A CANCER TYPE CHARACTERIZED BY THE ACTIVATION OF A MITOGEN-ACTIVATED PROTEIN KINASE

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Publication Date:
    May 30, 2024
  • Additional Information
    • Document Number:
      20240173380
    • Appl. No:
      18/248101
    • Application Filed:
      October 06, 2021
    • Abstract:
      The present invention refers to Cx43, preferably in combination with an inhibitor of a mitogen-activated protein kinase (MAPK) selected from the list consisting of: BRAF, RAS, MEK or ERK, for use in the treatment of cancer wherein the cancer is characterized by the activation of mitogen-activated protein kinase (MAPK) selected from the list consisting of: BRAF, RAS, MEK or ERK.
    • Claim:
      1. A method of treating cancer in a subject in need thereof, wherein the cancer is characterized by the activation of a mitogen-activated protein kinase (MAPK) selected from the group consisting of: BRAF, RAS, MEK, and ERK, comprising administering to the subject in need thereof a therapeutically effective amount of Connexin 43.
    • Claim:
      2. The method of claim 1, wherein the cancer is characterized by the activation of BRAF or NRAS.
    • Claim:
      3. The method of claim 1, wherein the cancer is melanoma, colon cancer, lung cancer, or breast cancer.
    • Claim:
      4. The method of claim 1, wherein Connexin 43 is administered to the subject before, after, or simultaneously to a treatment with an inhibitor of a mitogen-activated protein kinase (MAPK) selected from the group consisting of: BRAF, RAS, MEK, and ERK.
    • Claim:
      5. The method of claim 1, wherein Connexin 43 is administered to the subject before, after, or simultaneously to a treatment with a BRAF or a MEK inhibitor.
    • Claim:
      6. The method of claim 1, wherein Connexin 43 is administered to the subject before, after, or simultaneously to a treatment with dabrafenib, trametinib, vemurafenib, encorafenib, cobimetinib, or binimetinib.
    • Claim:
      7. The method of claim 1, wherein Connexin 43 is administered to the subject before, after, or simultaneously to a treatment with a senolytic agent.
    • Claim:
      8. A combination drug product comprising Connexin 43 and an inhibitor of a mitogen-activated protein kinase (MAPK) selected from the group consisting of: BRAF, RAS, MEK, and ERK.
    • Claim:
      9. The combination drug product of claim 8, comprising Connexin 43 and a BRAF or a MEK inhibitor.
    • Claim:
      10. The combination drug product of claim 8, comprising Connexin 43 and dabrafenib, trametinib, vemurafenib, encorafenib, cobimetinib, or binimetinib.
    • Claim:
      11. The combination drug product of claim 8, further comprising a senolytic agent.
    • Claim:
      12. A pharmaceutical composition comprising the combination drug product of claim 8, and, optionally, a pharmaceutically acceptable excipients or carriers.
    • Claim:
      13. A method of treating cancer in a subject in need thereof, wherein the cancer is characterized by the activation of a mitogen-activated protein kinase (MAPK) selected from the group consisting of: BRAF, RAS, MEK, and ERK, comprising administering to the subject in need thereof a pharmaceutical composition of claim 12, wherein Connexin 43 is administered by using a delivery vehicle.
    • Claim:
      14. The method of claim 13, wherein the delivery vehicle is a nanoparticle, an extracellular vesicle, or an expression vector which encodes Connexin 43.
    • Claim:
      15. The method of claim 7, wherein the senolytic agent is navitoclax.
    • Claim:
      16. The combination drug product of claim 11, wherein the senolytic agent is navitoclax.
    • Current International Class:
      61; 61; 61; 61; 61; 61; 61; 61
    • Accession Number:
      edspap.20240173380